Endocrinology Drugs Market Worth $48 Billion By 2030: IndustryARC

Endocrinology Drugs Market size is expected to reach $48 billion by 2030 after growing at a CAGR of 7.8% during the forecast period 2024-2030 according to the latest market research report published by IndustryARC. Rising prevalence of endocrine disorders, growing geriatric population and the increasing investment in healthcare propel the demand for endocrinology, finds IndustryARC in its recent report, titled “Endocrinology Drugs Market By Therapy Type (Hormone Replacement Therapy (HRT), Hormone Suppression Therapy, Diabetes Medications, Others), By Chemical Structure (Peptide Hormones, Steroids, Amino Acid Derivatives, Fatty Acid Derivatives (Eicosanoids), Others), By Organ/Gland Targeted (Thyroid Gland, Pancreas, Adrenal Glands, Pituitary Gland, Parathyroid Glands, Reproductive Glands, Others), By End Use Industry(Hospitals, Ambulatory Surgical Centers, Others), By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030”

The rise in endocrine disorders like diabetes and thyroid issues is the main driver for the Endocrinology Drugs market. This growth is fueled by an aging population and better detection methods. Many endocrine conditions are chronic requiring long-term medication use and diabetes with its high prevalence, is a particularly strong driver due to the constant need for new management options. Diabetes and Thyroid disorders are among the most common lifestyle problems among Indian people in 2022 according to the IndiaFit Report 2022 – 2023, published by GOQii. The percentage of the population with Diabetes has increased from 15% in 2020 to 17% in 2022. 7% of people are suffering from Thyroid-related issues, out of which women are more affected by it than men. Therefore, there is an ongoing need for endocrinology drugs to treat these conditions.

Geographically, North America held the largest share with 37% of the overall market in 2023 and it is poised to dominate the market over the period 2024-2030. North America, particularly the United States, faces a high prevalence of conditions like diabetes, thyroid disorders, and obesity. The United States, faces a high prevalence of conditions like diabetes, thyroid disorders, and obesity.  According to American Thyroid Association, an estimated 20 million Americans have some form of thyroid disease and up to 60% of those with thyroid disease are unaware of their condition. These factors create a significant demand for Endocrinology Drugs. 

By therapy type, diabetes medication is the largest segment. Diabetes is increasing at an alarming rate in the United States. According to the CDC’s (Centers for Disease Control) National Diabetes Statistics Report for 2022 cases of diabetes have risen to an estimated 37.3 million Diabetes is associated with complications such as heart disease, stroke, blindness, kidney failure and other serious conditions. Thus, diabetes management is very crucial for those that have diabetes. The global diabetic population set to reach around 700 million by 2045, as per the International Diabetes Federation (IDF). 

Growing investment in healthcare can have a significant positive impact on the Endocrinology Drugs market. The Australian Government is investing in a stronger health system as part of a plan for a stronger future through an investment of approximately $200 billion in 2022–23, increasing to about $210 billion in 2025–26, with a total commitment of more than $800 billion over the next four years. Increased investment allows pharmaceutical companies and research institutions to develop new and improved Endocrinology Drugs for a wider range of conditions like new drugs with better efficacy, fewer side effects, or more convenient delivery methods and development of drugs for currently underserved areas in endocrinology, like rare diseases or complex conditions with limited treatment options.

AI-powered clinical decision support systems (CDSS) are revolutionizing Endocrinology Drugs treatment by providing a new level of precision and personalization. AI can analyze vast amounts of patient data, including medical history, lab results, genetic information, and lifestyle factors. This comprehensive analysis helps healthcare providers identify the most effective course of treatment for each individual. Personalized treatment plans based on AI analysis can lead to better health outcomes and improved quality of life for patients. AI tools can assist healthcare providers in explaining complex medical information to patients in a clear and concise way, fostering better understanding and adherence to treatment plans.

The introduction of new anti-obesity medications, particularly glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (Wegovy) and tirzepatide (Mounjaro/Zepbound), presents a remarkable opportunity for the endocrinology drugs market. These medications originally developed for the treatment of type 2 diabetes have shown significant efficacy in promoting weight loss, marking a pivotal advancement in obesity management. Novo Nordisk's Wegovy has demonstrated the ability to reduce body weight by up to 15%, while Eli Lilly's Mounjaro has achieved over a 20% reduction in clinical trials. This addresses the interconnected nature of diabetes and obesity as these conditions often coexist and exacerbate each other. The launch of these medications not only provides a new therapeutic option for obesity but also enhances the comprehensive management of type 2 diabetes, ultimately improving patient outcomes and quality of life. 

Diabetes Injection Pens Market- The Diabetes Injection Pens Market Size is estimated to reach $11.2 billion by 2028 and it is poised to grow at a CAGR of 6.1% over the forecast period of 2023-2028. Diabetic patients use an insulin pen or injection pen to regulate insulin.

Human Insulin Market- Human Insulin Market size is forecast to reach $27.81 billion by 2025, growing at a CAGR of 5.40% during the forecast period 2020-2025. Insulin is a peptide hormone, secreted in the pancreas by beta cells of the islets of Langerhans, and it helps to regulate glucose metabolism.

IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets. 

IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format which assists an intelligent and informed decision-making process.

Mr. Venkat Reddy

IndustryARC

Email: [email protected]